PMID- 36737590
OWN - NLM
STAT- MEDLINE
DCOM- 20230213
LR  - 20230304
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 40
IP  - 3
DP  - 2023 Feb 3
TI  - CAFs secrete CXCL12 to accelerate the progression and cisplatin resistance of 
      colorectal cancer through promoting M2 polarization of macrophages.
PG  - 90
LID - 10.1007/s12032-023-01953-7 [doi]
AB  - The purpose of this study was to investigate the effect of the interaction 
      between tumor-associated fibroblasts (CAFs) and macrophage polarization on 
      colorectal cancer (CRC) progression. Clinical tissue samples of CRC and health 
      volunteers were collected to isolate normal fibroblasts (NFs) and CAFs. LoVo, 
      HCT116, or THP-1 cells were co-cultured with NFs or CAFs. Immunofluorescence and 
      western blot detected the expression of related markers. MTT assay measured cell 
      viability and IC50. Cell proliferation and metastasis were detected through 
      colony formation and transwell assays. CRC mice models were constructed by 
      injection of HCT116 cells, with IHC assessing C-X-C Motif Chemokine Ligand 12 
      (CXCL12) expression. The proliferation, migration, invasion, and cisplatin (DDP) 
      resistance of CRC cells were apparently increased after co-culture with CAFs. 
      Compared to NFs, CAFs have a markedly higher ability to recruit macrophages and 
      promote macrophages M2 polarization by secreting CXCL12. Further experiments 
      affirmed that CXCL12 secreted by CAFs boosted proliferation, migration, invasion, 
      and DDP resistance of CRC cells via induction of the M2 polarization of 
      macrophages. In vivo experiments confirmed that CAFs promoted the progression of 
      CRC and DDP resistance by affecting M2 polarization through CXCL12. CAFs recruit 
      macrophages and secrete CXCL12 to induce M2 polarization of macrophages, thus 
      mediating cell function and DDP resistance of CRC.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Jiang, Hang
AU  - Jiang H
AD  - Department of Gastroenterology, The Yancheng School of Clinical Medicine of 
      Nanjing Medical University (Yancheng Third People's Hospital), Yancheng, 224008, 
      Jiangsu, China.
FAU - Ge, Haijue
AU  - Ge H
AD  - Department of Gastroenterology, The Yancheng School of Clinical Medicine of 
      Nanjing Medical University (Yancheng Third People's Hospital), Yancheng, 224008, 
      Jiangsu, China.
FAU - Shi, Yuanyuan
AU  - Shi Y
AD  - Department of Central Laboratory, The Yancheng School of Clinical Medicine of 
      Nanjing Medical University (Yancheng Third People's Hospital), Yancheng, 224008, 
      Jiangsu, China.
FAU - Yuan, Fang
AU  - Yuan F
AD  - Department of Central Laboratory, The Yancheng School of Clinical Medicine of 
      Nanjing Medical University (Yancheng Third People's Hospital), Yancheng, 224008, 
      Jiangsu, China.
FAU - Yue, Hongqin
AU  - Yue H
AUID- ORCID: 0000-0002-4159-4963
AD  - Department of Gastroenterology, The Yancheng School of Clinical Medicine of 
      Nanjing Medical University (Yancheng Third People's Hospital), Yancheng, 224008, 
      Jiangsu, China. yuehqqy1999@126.com.
LA  - eng
PT  - Journal Article
DEP - 20230203
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Chemokine CXCL12)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Cell Line, Tumor
MH  - Cell Movement/physiology
MH  - Cell Proliferation
MH  - *Cisplatin/pharmacology
MH  - *Colorectal Neoplasms/pathology
MH  - Macrophages/metabolism
MH  - Tumor Microenvironment
MH  - Fibroblasts/metabolism
MH  - Chemokine CXCL12/metabolism
OTO - NOTNLM
OT  - CXCL12
OT  - Cancer-associated fibroblast
OT  - Colorectal cancer
OT  - Macrophages M2 polarization
OT  - Tumor microenvironment
EDAT- 2023/02/04 06:00
MHDA- 2023/02/08 06:00
CRDT- 2023/02/03 23:39
PHST- 2022/08/23 00:00 [received]
PHST- 2023/01/15 00:00 [accepted]
PHST- 2023/02/03 23:39 [entrez]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
AID - 10.1007/s12032-023-01953-7 [pii]
AID - 10.1007/s12032-023-01953-7 [doi]
PST - epublish
SO  - Med Oncol. 2023 Feb 3;40(3):90. doi: 10.1007/s12032-023-01953-7.